Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.25 USD | -2.21% | -11.33% | +48.70% |
15/05 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
13/05 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.70% | 132.85Cr | |
+9.93% | 12TCr | |
+10.00% | 11TCr | |
-11.09% | 2.34TCr | |
-1.69% | 2.21TCr | |
-10.23% | 1.83TCr | |
-41.92% | 1.66TCr | |
-15.69% | 1.6TCr | |
+6.83% | 1.4TCr | |
+16.47% | 1.17TCr |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Aeglea BioTherapeutics to Restructure; Cuts 25% of Headcount, Appoints Jim Kastenmayer as Interim CEO